AstraZeneca faces securities fraud probe after trial failure causes stock drop
AstraZeneca disclosed that its Phase-3 trial for Wainua, a treatment for amyloid cardiomyopathy, failed to meet its primary endpoint, causing its stock to drop 5.7% on July 9, 2026. Following this, Pomerantz LLP announced an investigation into whethe...
